TrialThe oncologist2022

Phase II Single-Arm Study of Palbociclib and Cetuximab Rechallenge in Patients with KRAS/NRAS/BRAF Wild-Type Colorectal Cancer.

Jonathan D Sorah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.